Our Advisors

Arpeggio is advised by incredible entrepreneurs, scientists, and biopharma veterans spanning fields from medicinal chemistry, oncology, neurology, molecular biology, genomics, machine learning, and business development.

Amit is an entrepreneur turned investor. As a highly-regarded physician, Amit combines practical knowledge across the healthcare value-chain investing as a general partner at Builders VC. He brings entrepreneurial and operational experience as the founder and CMO of Intrinsic Imaging, and advises Arpeggio on funding opportunities and growth challenges.

Amit Mehta, MD, FRCP

Board Director
Builders VC

Joe was the President and CEO of KBI Biopharma from 2002 to 2016, growing the company from 10 employees to 1000+. Joe is currently the President and CEO of Bioventure Partners where he advises early-stage companies like Arpeggio.

Joe McMahon

Strategic Advisor
KBI Biopharma

John started his career at Bristol-Myers Squibb as a group leader of discovery chemistry. Currently, John advises early-stage companies on their medicinal chemistry design and interfaces with CROs to drive fast and accurate preclinical development.

John Dickson, PhD

Medicinal Chemistry

David has served as President & CEO of Lyric Pharmaceuticals, an ICU therapeutic development company which he founded, built and successfully funded, and as CMO and an early employee of Lucid Diagnostics, a medical device-diagnostic company which went public via IPO in 2021.

David Wurtman, MD, MBA

Business Development
Lyric Pharma

Robin Dowell merges genetics and computer science to investigate transcriptional regulation. In an “antedisciplinary” approach, Dr. Dowell ignores boundaries between disciplines to follow this biological problem wherever it leads. Dowell’s background is uniquely diverse; she holds bachelor’s degrees in both genetics and computer engineering from Texas A&M University, and received an M.S. in computer science and Ph.D. in biomedical engineering from Washington University in St. Louis.

Robin Dowell, PhD

BioFrontiers Institute
Scientific Founder

Dave started his career at GSK where he was the VP of Biological Platform Technology and Science, and more recently was the VP of Research Operations at Precision Biosciences. Dave advises Arpeggio on systems biology and our automated drug screening platform.

Dave Morris, PhD

Automation Advisor

Robert has 24 years of experience in the pharmaceutical industry and is the former Head of Oncology Discovery Research at both Bristol-Myers Squibb and Janssen Pharmaceuticals, part of the Johnson & Johnson group of companies.

Robert Kramer, PhD

Portage, BMS, J&J

Bill has led IP for companies like Advanced LiquidLogic, Illumina, and Grail. At Arpeggio, Bill is critical in helping define our patent strategy and portfolio around both our platform and novel chemical entities.

Bill Barrett

WSGR Counsel
Illumina, GRAIL


Interested in joining Arpeggio?
Check out the positions we're currently hiring for below.

Contact Us

Have questions? Interested in partnering with Arpeggio? Let us know.

Your message has been submitted.
We will get back to you within 24-48 hours.
Oops! Something went wrong.